New chemo cocktail aims to outperform standard care in colorectal cancer

NCT ID NCT07309289

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a new combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than the standard FOLFOX regimen for people with metastatic colorectal cancer that has not been treated before. About 144 participants will receive one of the two treatments. The study aims to see if the new combo can delay cancer growth and improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Irinotecan liposome, oxaliplatin, 5-FU, leucovorin, bevacizumab, cetuximab
What this could lead to: If successful, this could provide a more effective first-line treatment option for people with metastatic colorectal cancer, potentially improving survival and tumor shrinkage.
What could go wrong: This is a Phase 3 trial, but results may not show a significant benefit over standard therapy. Side effects from the combination chemotherapy and targeted drugs can be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

Shanghai Zhongshan Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.